NewsBenzingaTruist Securities Maintains Hold on M&T Bank, Lowers Price Target to $250 Truist Securities Maintains Hold on M&T Bank, Lowers Price Target to $250 Benzinga 2026.09.23 16:17 (GMT+0) Open on Benzinga Other news REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids NeoVolta Q4 EPS $(0.24) Misses $(0.09) Estimate, Sales $13.460K Miss $1.272M Estimate $100 Invested In EMCOR Group 15 Years Ago Would Be Worth This Much Today Airbnb Announces Broader Access To OpenAI Frontier Models For Its Engineering, Product Development Teams Stitch Fix Sees FY2027 Sales $1.310B-$1.360B vs $1.406B Est Arcturus Therapeutics Says ARCT-810 Generally Safe And Well Tolerated, Demonstrating Encouraging Activity Across Key Urea Cycle Biomarkers In Ongoing Phase 2 Study
REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids
Airbnb Announces Broader Access To OpenAI Frontier Models For Its Engineering, Product Development Teams
Arcturus Therapeutics Says ARCT-810 Generally Safe And Well Tolerated, Demonstrating Encouraging Activity Across Key Urea Cycle Biomarkers In Ongoing Phase 2 Study
